Rigel Historical Income Statement
| RIGL Stock | USD 26.04 1.00 3.99% |
Historical analysis of Rigel Pharmaceuticals income statement accounts such as Other Operating Expenses of 102.4 M, Research Development of 23.3 M, Cost Of Revenue of 6.8 M or Total Operating Expenses of 102.3 M can show how well Rigel Pharmaceuticals performed in making a profits. Evaluating Rigel Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Rigel Pharmaceuticals's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Rigel Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Rigel Pharmaceuticals is a good buy for the upcoming year.
Rigel |
About Rigel Income Statement Analysis
Rigel Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Rigel Pharmaceuticals shareholders. The income statement also shows Rigel investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Rigel Pharmaceuticals Income Statement Chart
Add Fundamental
Total Revenue
Total revenue comprises all receipts Rigel Pharmaceuticals generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Rigel Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Rigel Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Income Before Tax
Income Before Tax which can also be referred as pre-tax income is reported on Rigel Pharmaceuticals income statement and is an important metric when analyzing Rigel Pharmaceuticals profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability.Most accounts from Rigel Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Rigel Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rigel Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For more information on how to buy Rigel Stock please use our How to buy in Rigel Stock guide.At this time, Rigel Pharmaceuticals' Selling General Administrative is quite stable compared to the past year. Non Operating Income Net Other is expected to rise to about 936.5 K this year, although the value of Operating Income will most likely fall to (21.5 M).
| 2022 | 2023 | 2024 (projected) | Interest Income | 684K | 2.0M | 1.2M | Non Recurring | 1.3M | 1.2M | 1.1M |
Rigel Pharmaceuticals income statement Correlations
Click cells to compare fundamentals
Rigel Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Rigel Pharmaceuticals income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 2.5M | 706K | 1.2M | 998K | 1.2M | 1.8M | |
| Interest Expense | 335K | 1.4M | 4.9M | 3.7M | 6.9M | 7.2M | |
| Total Revenue | 59.3M | 108.6M | 149.2M | 120.2M | 116.9M | 122.7M | |
| Gross Profit | 58.4M | 107.7M | 148.2M | 118.5M | 109.8M | 115.3M | |
| Other Operating Expenses | 128.4M | 137.6M | 158.2M | 174.5M | 137.4M | 102.4M | |
| Operating Income | (69.1M) | (29.0M) | (9.0M) | (54.2M) | (20.5M) | (21.5M) | |
| Ebit | (69.1M) | (28.4M) | (12.4M) | (54.9M) | (18.2M) | (19.1M) | |
| Research Development | 52.9M | 60.1M | 65.2M | 60.3M | 24.5M | 23.3M | |
| Ebitda | (66.6M) | (27.7M) | (11.3M) | (53.9M) | (17.0M) | (17.8M) | |
| Cost Of Revenue | 906K | 895K | 1.1M | 1.7M | 7.1M | 6.8M | |
| Total Operating Expenses | 127.5M | 136.7M | 157.1M | 172.7M | 130.3M | 102.3M | |
| Net Income | (66.5M) | (30.4M) | (17.9M) | (61.6M) | (25.1M) | (26.3M) | |
| Income Tax Expense | (348K) | 647K | 605K | 3.0M | 2.3M | 2.4M | |
| Selling General Administrative | 74.6M | 76.6M | 91.9M | 112.5M | 111.1M | 116.6M | |
| Income Before Tax | (66.9M) | (29.7M) | (17.3M) | (58.6M) | (25.1M) | (26.3M) | |
| Total Other Income Expense Net | 2.2M | (771K) | (4.8M) | (3.0M) | (4.6M) | (4.4M) | |
| Net Income Applicable To Common Shares | (66.9M) | (29.7M) | (17.9M) | (58.6M) | (67.4M) | (70.7M) | |
| Net Income From Continuing Ops | (66.9M) | (29.7M) | (17.9M) | (58.6M) | (24.4M) | (25.6M) | |
| Non Operating Income Net Other | 2.5M | 582K | 47K | 684K | 786.6K | 936.5K | |
| Interest Income | 2.5M | 582K | 47K | 684K | 2.0M | 1.2M | |
| Net Interest Income | 2.2M | (771K) | (4.8M) | (3.0M) | (4.0M) | (3.8M) | |
| Reconciled Depreciation | 683K | 706K | 1.2M | 998K | 1.2M | 917.2K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rigel Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For more information on how to buy Rigel Stock please use our How to buy in Rigel Stock guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rigel Pharmaceuticals. If investors know Rigel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rigel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.48) | Earnings Share 0.27 | Revenue Per Share 8.979 | Quarterly Revenue Growth 0.966 | Return On Assets 0.0461 |
The market value of Rigel Pharmaceuticals is measured differently than its book value, which is the value of Rigel that is recorded on the company's balance sheet. Investors also form their own opinion of Rigel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rigel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rigel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rigel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rigel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rigel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rigel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.